Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Vinaixa, Maria ^a,b   Rodriguez, Miguel Angel ^a,b   Samino, Sara ^a,b   Díaz, Marta ^c,d   Beltran, Antoni ^a   Mallol, Roger ^a,b   Bladé, Cinta ^a,b   Ibañez, Lourdes ^c,d   Correig, Xavier ^a,b   Yanes, Oscar ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; AZELAIC ACID; CORIOLIC ACID; DIMORPHECOLIC ACID; DROSPIRENONE PLUS ETHINYLESTRADIOL; FLUTAMIDE; GLUTARIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OXIDIZED LOW DENSITY LIPOPROTEIN; PIOGLITAZONE; TESTOSTERONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BIOLOGICAL MARKER; DICARBOXYLIC ACID; LINOLEIC ACID; LIPOPROTEIN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CAROTID ARTERY; CLINICAL ARTICLE; DRUG MECHANISM; ELECTROSPRAY MASS SPECTROMETRY; EVENING DOSAGE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LONGITUDINAL STUDY; LOW DRUG DOSE; MASS FRAGMENTOGRAPHY; METABOLOMICS; MORNING DOSAGE; OVARY POLYCYSTIC DISEASE; PROTON NUCLEAR MAGNETIC RESONANCE; TIME OF FLIGHT MASS SPECTROMETRY; ABDOMINAL FAT; BLOOD; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; GAS CHROMATOGRAPHY; HEALTH; METABOLISM; METHODOLOGY; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION REDUCTION REACTION; RANDOMIZED CONTROLLED TRIAL;

ABDOMINAL FAT; BIOLOGICAL MARKERS; CAROTID INTIMA-MEDIA THICKNESS; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, LIQUID; DICARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FLUTAMIDE; HEALTH; HUMANS; LINOLEIC ACID; LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; METABOLOMICS; METFORMIN; MULTIVARIATE ANALYSIS; OXIDATION-REDUCTION; POLYCYSTIC OVARY SYNDROME; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THIAZOLIDINEDIONES; YOUNG ADULT;

EID: 83455262481     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029052     Document Type: Article

References (43)

1. Ibanez L, Valls C, de Zegher F, (2006) Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio. Human Reproduction 21: 451-456.
2. Lambrinoudaki I, (2011) Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome. Maturitas 68: 13-16.
3. McGowan M, (2011) Polycystic Ovary Syndrome: A Common Endocrine Disorder and Risk Factor for Vascular Disease. Current Treatment Options in Cardiovascular Medicine pp. 1-13.
4. Macut D, Panidis D, Glisić B, Spanos N, Petakov M, (2008) Lipid and lipoprotein profile in women with polycystic ovary syndrome. Can J Physiol Pharmacol 86: 199-204.
5. Macut D, Damjanovic S, Panidis D, Spanos N, Glisic B, et al. (2006) Oxidised low-density lipoprotein concentration- early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol 155: 131-136.
6. Sabuncu T, Vural H, Harma M, Harma M, (2001) Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clinical Biochemistry 34: 407-413.
7. Wild RA, (2002) Long-term health consequences of PCOS. Human Reproduction Update 8: 231-241.
8. Legro RS, (2003) Polycystic Ovary Syndrome and Cardiovascular Disease: A Premature Association? Endocrine Reviews 24: 302-312.
9. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, et al. (2004) Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89: 5454-5461.
10. Ibanez L, Lopez-Bermejo A, del Rio L, Enriquez G, Valls C, et al. (2007) Combined low-dose pioglitazone, flutamide, and metformin for women with androgen excess. Journal Of Clinical Endocrinology And Metabolism 92: 1710-1714.
11. Ibanez L, Lopez-Bermejo A, Diaz M, Enriquez G, Valls C, et al. (2008) Pioglitazone (7.5 mg/day) added to flutamide-metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin. Clinical Endocrinology 68: 317-320.
12. Ibáñez L, López-Bermejo A, Díaz M, Enríquez G, Del Río L, et al. (2009) Low-dose pioglitazone and low-dose flutamide added to metformin and estro-progestagens for hyperinsulinemic women with androgen excess: add-on benefits disclosed by a randomized double-placebo study over 24 months. Clin Endocrinol 71: 351-357.
13. Ibañez L, López-Bermejo A, Díaz M, Enríquez G, Del Río L, et al. (2010) Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months. Gynecological Endocrinology 26: 869-873.
14. Lenz EM, Bright J, Knight R, Wilson ID, Major H, (2004) Cyclosporin A-induced changes in endogenous metabolites in rat urine: A metabonomic investigation using high field 1H NMR spectroscopy, HPLC-TOF/MS and chemometrics. Journal of Pharmaceutical and Biomedical Analysis 35: 599-608.
15. Sieber M, Wagner S, Rached E, Amberg A, Mally A, et al. (2009) Metabonomic study of ochratoxin a toxicity in rats after repeated administration: phenotypic anchoring enhances the ability for biomarker discovery. Chem Res Toxicol 22: 1221-1231.
16. Williams R, Lenz EM, Wilson AJ, Granger J, Wilson ID, et al. (2006) A multi-analytical platform approach to the metabonomic analysis of plasma from normal and zucker (fa/fa) obese rats. Molecular BioSystems 2: 174-183.
17. Dunn WB, Bailey NJC, Johnson HE, (2005) Measuring the metabolome: current analytical technologies. Analyst 130: 606-625.
18. Moco S, Vervoort J, Moco S, Bino RJ, De Vos RCH, et al. (2007) Metabolomics technologies and metabolite identification. TrAC Trends in Analytical Chemistry 26: 855-866.
19. Lenz EM, Wilson ID, (2006) Analytical Strategies in Metabonomics. Journal of Proteome Research 6: 443-458.
20. Dunn WB, Ellis DI, (2005) Metabolomics: Current analytical platforms and methodologies. TrAC Trends in Analytical Chemistry 24: 285-294.
21. Mallol R, Rodríguez M, Heras M, Vinaixa M, Cañellas N, et al. (2011) Surface fitting of 2D diffusion-edited 1H NMR spectroscopy data for human plasma lipoproteins characterization. Metabolomics pp. 1-11.
22. Palazoglu M, Fiehn O, (2009) Metabolite Identification in Blood Plasma Using GC/MS and the Agilent Fiehn GC/MS Metabolomics RTL Library. Agilent Application Note.
23. Jansen JJ, Hoefsloot HCJ, van der Greef J, Timmerman ME, Smilde AK, (2005) Multilevel component analysis of time-resolved metabolic fingerprinting data. Analytica Chimica Acta 530: 173-183.
24. Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G, (2006) XCMS: Processing Mass Spectrometry Data for Metabolite Profiling Using Nonlinear Peak Alignment, Matching, and Identification. Analytical Chemistry 78: 779-787.
25. Jankowski J, Nofer JR, Tepel M, Griewel B, Schläter H, et al. (1998) Identification of oxidized low-density lipoprotein in human serum by NMR spectroscopy. Clin Sci 95: 489-495.
26. Lee SH, Blair IA, (2001) Oxidative DNA Damage and Cardiovascular Disease. Trends in Cardiovascular Medicine 11: 148-155.
27. Lee SH, Williams MV, Blair IA, (2005) Targeted chiral lipidomics analysis. Prostaglandins & Other Lipid Mediators 77: 141-157.
28. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SS, et al. (1989) Low density lipoprotein undergoes oxidative modification in vivo. Proceedings of the National Academy of Sciences of the United States of America 86: 1372-1376.
29. Haberland ME, Olch CL, Folgelman AM, (1984) Role of lysines in mediating interaction of modified low density lipoproteins with the scavenger receptor of human monocyte macrophages. Journal of Biological Chemistry 259: 11305-11311.
30. Raghavamenon A, Garelnabi M, Babu S, Aldrich A, Litvinov D, et al. (2009) Alpha-Tocopherol Is Ineffective in Preventing the Decomposition of Preformed Lipid Peroxides and May Promote the Accumulation of Toxic Aldehydes: A Potential Explanation for the Failure of Antioxidants to Affect Human Atherosclerosis. Antioxidants & Redox Signaling 11: 1237-1248.
31. Januszewski AS, Alderson NL, Jenkins AJ, Thorpe SR, Baynes JW, (2005) Chemical modification of proteins during peroxidation of phospholipids. J Lipid Res 46: 1440-1449.
32. Tokumura A, Toujima M, Yoshioka Y, Fukuzawa K, (1996) Lipid peroxidation in low density lipoproteins from human plasma and egg yolk promotes accumulation of 1-acyl analogues of platelet-activating factor-like lipids. Lipids 31: 1251-1258.
33. Chen R, Yang L, McIntyre TM, (2007) Cytotoxic Phospholipid Oxidation Products. Journal of Biological Chemistry 282: 24842-24850.
34. Januszewski AS, Jenkins AJ, Baynes JW, Thorpe SR, (2005) Lipid-Derived Modifications of Plasma Proteins in Experimental and Human Diabetes. Annals of the New York Academy of Sciences 1043: 404-412.
35. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, et al. (2000) Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study. Clinical Therapeutics 22: 1395-1409.
36. Charbonnel B, Schernthaner G, Brunetti P, Matthews D, Urquhart R, et al. (2005) Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 48: 1093-1104.
37. Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, et al. (2006) Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. Journal of Clinical Pharmacy and Therapeutics 31: 375-383.
38. Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, et al. (2007) Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Internal Medicine Journal 37: 79-86.
39. Hanefeld M, (2009) The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes, Obesity and Metabolism 11: 742-756.
40. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JPD, (2004) Favorable Effects of Pioglitazone and Metformin Compared With Gliclazide on Lipoprotein Subfractions in Overweight Patients With Early Type 2 Diabetes. Diabetes Care 27: 41-46.
41. Winkler K, Konrad T, Füllert S, Friedrich I, Destani R, et al. (2003) Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension. Diabetes Care 26: 2588-2594.
42. Iida KT, Kawakami Y, Suzuki M, Shimano H, Toyoshima H, et al. (2003) Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. American Journal of Physiology- Endocrinology And Metabolism 284: E1125-E1130.
43. Steinberg D, (1990) Arterial Metabolism of Lipoproteins in Relation to Atherogenesis. Annals of the New York Academy of Sciences 598: 125-135.